Cargando…

Antiviral drugs against SARS-CoV-2

The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 d...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiello, Tommaso Francesco, García-Vidal, Carolina, Soriano, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717461/
https://www.ncbi.nlm.nih.gov/pubmed/36285850
http://dx.doi.org/10.37201/req/s03.03.2022
_version_ 1784842906857635840
author Aiello, Tommaso Francesco
García-Vidal, Carolina
Soriano, Alex
author_facet Aiello, Tommaso Francesco
García-Vidal, Carolina
Soriano, Alex
author_sort Aiello, Tommaso Francesco
collection PubMed
description The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 days that is the window of opportunity for giving an antiviral. Accordingly, early and rapid diagnostic of the infection in the outpatient clinic is essential as well as the availability of oral agents that can be easily prescribe. Remdesivir has demonstrated its efficacy in hospitalized patients requiring oxygen support and in mild/moderate cases to avoid the hospitalization, however, the intravenous administration limits its use among outpatients. Molnupiravir and nirmatrelvir/ ritonavir are potent oral antiviral agents. In the present review we discuss the potential targets against SARS-CoV-2, and an overview of the main characteristics and clinical results with the available antiviral agents for the treatment of SARS-CoV-2.
format Online
Article
Text
id pubmed-9717461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-97174612022-12-08 Antiviral drugs against SARS-CoV-2 Aiello, Tommaso Francesco García-Vidal, Carolina Soriano, Alex Rev Esp Quimioter Approach to management of SARS-CoV-2 infection The use of antiviral drugs represents an important progress in the therapeutic management of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and mortality. In immunocompetent host, peak viral replication occurs around the symptom’s onset, and it prolongs for 5 to 7 days that is the window of opportunity for giving an antiviral. Accordingly, early and rapid diagnostic of the infection in the outpatient clinic is essential as well as the availability of oral agents that can be easily prescribe. Remdesivir has demonstrated its efficacy in hospitalized patients requiring oxygen support and in mild/moderate cases to avoid the hospitalization, however, the intravenous administration limits its use among outpatients. Molnupiravir and nirmatrelvir/ ritonavir are potent oral antiviral agents. In the present review we discuss the potential targets against SARS-CoV-2, and an overview of the main characteristics and clinical results with the available antiviral agents for the treatment of SARS-CoV-2. Sociedad Española de Quimioterapia 2022-10-24 2022 /pmc/articles/PMC9717461/ /pubmed/36285850 http://dx.doi.org/10.37201/req/s03.03.2022 Text en © The Author 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Approach to management of SARS-CoV-2 infection
Aiello, Tommaso Francesco
García-Vidal, Carolina
Soriano, Alex
Antiviral drugs against SARS-CoV-2
title Antiviral drugs against SARS-CoV-2
title_full Antiviral drugs against SARS-CoV-2
title_fullStr Antiviral drugs against SARS-CoV-2
title_full_unstemmed Antiviral drugs against SARS-CoV-2
title_short Antiviral drugs against SARS-CoV-2
title_sort antiviral drugs against sars-cov-2
topic Approach to management of SARS-CoV-2 infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717461/
https://www.ncbi.nlm.nih.gov/pubmed/36285850
http://dx.doi.org/10.37201/req/s03.03.2022
work_keys_str_mv AT aiellotommasofrancesco antiviraldrugsagainstsarscov2
AT garciavidalcarolina antiviraldrugsagainstsarscov2
AT sorianoalex antiviraldrugsagainstsarscov2